Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
A cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.
Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Neyns, B., et al. 2010. Cancer116, 2868. Marchesi, F., et al. 2007. Pharmacol. Res.56, 275. Chakravarti, A., et al. 2006. Clin. Cancer Res.12, 4738. Natsume, A., et al. 2005. Cancer Res.65, 7573. Jen, J.F., et al. 2000. Pharm. Res.17, 1284.
Toxic by inhalation, in contact with skin and if swallowed. Irritating to eyes, respiratory system and skin. May cause cancer. May cause heritable genetic damage.
S Phrase
S: 26-36-45
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code
Ambient Temperature Only
Toxicity
Harmful & Carcinogenic / Teratogenic
Storage
+2°C to +8°C
Protect from Light
Protect from light
Do not freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Neyns, B., et al. 2010. Cancer116, 2868. Marchesi, F., et al. 2007. Pharmacol. Res.56, 275. Chakravarti, A., et al. 2006. Clin. Cancer Res.12, 4738. Natsume, A., et al. 2005. Cancer Res.65, 7573. Jen, J.F., et al. 2000. Pharm. Res.17, 1284.
数据表
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.
Form
Off-white solid
Intert gas (Yes/No)
Packaged under inert gas
CAS number
85622-93-1
Chemical formula
C₆H₆N₆O₂
Structure formula
Purity
≥99% by HPLC
Solubility
DMSO (25 mg/ml)
Storage
Protect from light
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Harmful & Carcinogenic / Teratogenic
References
Neyns, B., et al. 2010. Cancer116, 2868. Marchesi, F., et al. 2007. Pharmacol. Res.56, 275. Chakravarti, A., et al. 2006. Clin. Cancer Res.12, 4738. Natsume, A., et al. 2005. Cancer Res.65, 7573. Jen, J.F., et al. 2000. Pharm. Res.17, 1284.